Flynn Pharma’s reply to BrunetBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f358 (Published 22 January 2013) Cite this as: BMJ 2013;346:f358
- David Walters, director1
- 1Flynn Pharma, Stevenage SG1 3EE, UK
In response to Brunet,1 2 it is complex and expensive to manage the end of the life cycle of a declining product that is essential for patients. The most important consideration for patients was that the capsules were retained on the market, which would not have been …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial